PureTech Health Announces Positive Phase 2b Extension Data for Deupirfenidone in IPF; Phase 3 Trial Design Update Expected Q4 2025
PureTech Health plc announced positive results from the Phase 2b extension of its ELEVATE IPF trial for deupirfenidone in idiopathic pulmonary fibrosis (IPF). Participants who switched to deupirfenidone after initial placebo or pirfenidone treatment showed stabilized lung function over 26 weeks. These findings were presented at the 2025 European Respiratory Society Congress. Regulatory discussions for the Phase 3 trial design are ongoing, with an update expected in Q4 2025.
PureTech Health plc has announced new data from the open-label extension (OLE) of its Phase 2b ELEVATE IPF trial evaluating deupirfenidone (LYT-100) in individuals with idiopathic pulmonary fibrosis (IPF). The results indicate that participants who initially received placebo or pirfenidone during the randomized phase and subsequently switched to deupirfenidone for an additional 26 weeks experienced stabilization of lung function. These findings, which further support the safety and efficacy profile of deupirfenidone observed in the main 26-week study, were delivered in a late-breaking oral presentation at the 2025 European Respiratory Society (ERS) Congress in Amsterdam. PureTech Health noted that regulatory discussions regarding the Phase 3 trial design are ongoing, with an update expected in the fourth quarter of 2025. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PureTech Health plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20250928954610) on September 29, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
